11:06 AM EDT, 10/31/2024 (MT Newswires) -- Merus's (MRUS) shares dipped 2% in early Thursday trading after the immuno-oncology company reported a Q3 net loss of $1.46 per diluted share, wider than its loss of $0.43 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.87.

Revenue for the quarter ended Sept. 30 was $11.8 million, compared with $11 million a year earlier.

Analysts surveyed by Capital IQ expected $8.7 million.

Price: 50.08, Change: -1.20, Percent Change: -2.34